Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations–State-of-the-Art

Basit Öğe Kaydı
dc.contributor.authorDimakakos, Evangelos
dc.contributor.authorGomatou, Georgia
dc.contributor.authorCatalano, Mariella
dc.contributor.authorOlinic, Dan-Mircea
dc.contributor.authorSpyropoulos, Alex C.
dc.contributor.authorFalanga, Anna
dc.contributor.authorMaraveyas, Anthony
dc.contributor.authorLiew, Aaron
dc.contributor.authorSchulman, Sam
dc.contributor.authorBelch, Jill
dc.contributor.authorGerotziafas, Grigorios
dc.contributor.authorMarschang, Peter
dc.contributor.authorKarahan, Oğuz
dc.date.accessioned2023-10-02T06:32:47Z
dc.date.available2023-10-02T06:32:47Z
dc.date.issued2022
dc.departmentALKÜ, Fakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü
dc.description.abstractCancer and COVID-19 are both well-established risk factors predisposing to thrombosis. Both disease entities are correlated with increased incidence of venous thrombotic events through multifaceted pathogenic mechanisms involving the interaction of cancer cells or SARS-CoV2 on the one hand and the coagulation system and endothelial cells on the other hand. Thromboprophylaxis is recommended for hospitalized patients with active cancer and high-risk outpatients with cancer receiving anticancer treatment. Universal thromboprophylaxis with a high prophylactic dose of low molecular weight heparins (LMWH) or therapeutic dose in select patients, is currently indicated for hospitalized patients with COVID-19. Also, prophylactic anticoagulation is recommended for outpatients with COVID-19 at high risk for thrombosis or disease worsening. However, whether there is an additive risk of thrombosis when a patient with cancer is infected with SARSCoV2 remains unclear. In the current review, we summarize and critically discuss the literature regarding the epidemiology of thrombotic events in patients with cancer and concomitant COVID-19, the thrombotic risk assessment, and the recommendations on thromboprophylaxis for this subgroup of patients. Current data do not support an additive thrombotic risk for patients with cancer and COVID-19. Of note, patients with cancer have less access to intensive care unit care, a setting associated with high thrombotic risk. Based on current evidence, patients with cancer and COVID-19 should be assessed with well-established risk assessment models for medically ill patients and receive thromboprophylaxis, preferentially with LMWH, according to existing recommendations. Prospective trials on well-characterized populations do not exist. © 2022 International Institute of Anticancer Research. All rights reserved.
dc.identifier.doi10.21873/anticanres.15815
dc.identifier.endpage3274en_US
dc.identifier.issue7en_US
dc.identifier.scopusqualityQ3
dc.identifier.startpage3261en_US
dc.identifier.urihttps://www.scopus.com/record/display.uri?eid=2-s2.0-85133288196&origin=resultslist&sort=plf-f&src=s&nlo=&nlr=&nls=&sid=20c4fe371b9b908d4f7e419f791331ff&sot=aff&sdt=cl&cluster=scofreetoread%2c%22all%22%2ct&sl=72&s=AF-ID%28%22Alanya+Alaaddin+Keykubat+University%22+60198720%29+AND+SUBJAREA%28MEDI%29&relpos=49&citeCnt=4&searchTerm=
dc.identifier.urihttps://hdl.handle.net/20.500.12868/2357
dc.identifier.urihttps://ar.iiarjournals.org/content/42/7/3261
dc.identifier.volume42en_US
dc.indekslendigikaynakScopus
dc.language.isoen
dc.relation.ispartofAnticancer Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAnticoagulation
dc.subjectCAT
dc.subjectCOVID-19
dc.subjectReview
dc.subjectThromboprophylaxis
dc.titleThromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations–State-of-the-Art
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Thromboembolic-Disease-in-Patients-With-Cancer-and-COVID19-Risk-Factors-Prevention-and-Practical-Thromboprophylaxis-RecommendationsStateoftheArtAnticancer-Research.pdf
Boyut:
620.89 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu